Wan X, et al. - From the US payer perspective, researchers assessed the cost-effectiveness of atezolizumab in the treatment of metastatic non–small cell lung cancer (NSCLC) as first-line therapy. They constructed a Markov model and compared first-line treatment using the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) or the combination of bevacizumab, carboplatin, and paclitaxel (BCP) or carboplatin and paclitaxel (CP), in terms of lifetime cost and efficacy. At a willingness-to-pay threshold of $100,000 per quality-adjusted life-year, first-line treatment with ABCP was not cost-effective vs BCP or CP in patients with metastatic, nonsquamous NSCLC, from the US payer perspective.